|
SELECT PUBLICATIONS
Burstein HJ et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing
metastatic breast cancer: Multicenter phase II trial with clinical outcomes,
analysis of serum tumor markers as predictive factors, and cardiac surveillance
algorithm. J Clin Oncol 2003;21(15):2889-95. Abstract
Cobleigh MA et al. A phase I/II dose-escalation trial of bevacizumab in previously
treated metastatic breast cancer. Semin Oncol 2003;30(5 Suppl 16):117-24. Abstract
Hudis CA. Clinical implications of antiangiogenic therapies. Oncology (Williston Park) 2005;19(4 Suppl 3):26-31. Abstract
Ignoffo RJ. Overview of bevacizumab: A new cancer therapeutic strategy targeting
vascular endothelial growth factor. Am J Health Syst Pharm 2004;61(21 Suppl 5):21-6.
Abstract
Miller KD et al. E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus
bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Presentation. ASCO 2005. No abstract available
Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab
plus capecitabine in patients with previously treated metastatic breast cancer. J Clin
Oncol 2005;23(4):792-9. Abstract
Miller KD. Recent translational research: Antiangiogenic therapy for breast cancer -
where do we stand? Breast Cancer Res 2004;6(3):128-32. Abstract
Moses MA et al. A role for antiangiogenic therapy in breast cancer. Curr Oncol Rep 2004;6(1):42-8. Abstract
Pegram MD et al. Phase I combined biological therapy of breast cancer using two
humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular
endothelial growth factor (VEGF). San Antonio Breast Cancer Symposium 2004;
Abstract 3039.
Perez EA et al. NCCTG N9831: May 2005 update. Presentation. ASCO 2005;Abstract 556.
Piccart-Gebhart MJ. First results of the HERA trial. Presentation. ASCO 2005a. No abstract
available
Piccart-Gebhart MJ et al. Trastuzumab after adjuvant chemotherapy in HER 2-positive
breast cancer. N Engl J Med 2005b;353(16):1659-72. Abstract
Romond EH et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or
without trastuzumab as adjuvant therapy for patients with HER-2 positive operable
breast cancer — Combined analysis of NSABP-B31/NCCTG-N9831. Presentation. ASCO
2005a. No abstract available
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER 2 positive
breast cancer. N Engl J Med 2005b;353(16):1673-84. Abstract
Rugo HS. Bevacizumab in the treatment of breast cancer: Rationale and current data. Oncologist 2004;9 Suppl 1:43-9. Abstract
Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005;23(8):1782-90. No
abstract available
Slamon D et al. BCIRG006 — Randomized Phase III trial comparing AC-T vs ACTH
TCH in HER2 positive node positive or high risk node negative breast cancer. Presentation. NSABP meeting. September 2005. No abstract available
Tan-Chiu E et al. Assessment of cardiac dysfunction in a randomized trial comparing
doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab
as adjuvant therapy in node-positive, human epidermal growth factor receptor
2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-19. Abstract
Vogel CL et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment
of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26.
Abstract
|
